{"date":"2025-12-29","count":23,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4116-2025-12-29-2237-5uvxxq","company_id":"4116","company":"明基醫","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"22:37:31","subject":"公告本公司經董事會決議通過投資敦品創新伍號杏林股份有限公司","clause":"第20款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：明基醫（4116），2025-12-29 22:37，「公告本公司經董事會決議通過投資敦品創新伍號杏林股份有限公司」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6734-2025-12-29-2120-f03jti","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2025-12-29","time":"21:20:56","subject":"公告本公司114年11月份自結財務報告之負債比率、流動比率、速動比率、預估未來三個月現金收支情形及銀行可使用融資額度情形","clause":"第44款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2025-12-29 21:20，「公告本公司114年11月份自結財務報告之負債比率、流動比率、速動比率、預估未來三個月現金收支情形及銀行可使用融資額度情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4116-2025-12-29-1937-vxmvun","company_id":"4116","company":"明基醫","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"19:37:56","subject":"代重要子公司凱圖國際股份有限公司公告法人董事代表人異動","clause":"第6款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：明基醫（4116），2025-12-29 19:37，「代重要子公司凱圖國際股份有限公司公告法人董事代表人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4116-2025-12-29-1929-mme6ws","company_id":"4116","company":"明基醫","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"19:29:09","subject":"代重要子公司怡安醫療器材股份有限公司公告董事長暨總經理異動","clause":"第6款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：明基醫（4116），2025-12-29 19:29，「代重要子公司怡安醫療器材股份有限公司公告董事長暨總經理異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4116-2025-12-29-1904-qhietx","company_id":"4116","company":"明基醫","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"19:04:18","subject":"代重要子公司怡安醫療器材股份有限公司公告法人董事代表人異動","clause":"第6款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：明基醫（4116），2025-12-29 19:04，「代重要子公司怡安醫療器材股份有限公司公告法人董事代表人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4116-2025-12-29-1839-sqgrt0","company_id":"4116","company":"明基醫","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"18:39:10","subject":"公告本公司法人董事代表人異動","clause":"第6款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：明基醫（4116），2025-12-29 18:39，「公告本公司法人董事代表人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4116-2025-12-29-1828-wr0tu2","company_id":"4116","company":"明基醫","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"18:28:52","subject":"公告本公司總經理異動","clause":"第6款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：明基醫（4116），2025-12-29 18:28，「公告本公司總經理異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2025-12-29-1824-nct01n","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2025-12-29","time":"18:24:03","subject":"本公司受邀參加凱基證券舉辦之法人座談會","clause":"第12款","fact_date":"2026-01-23","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2025-12-29 18:24，「本公司受邀參加凱基證券舉辦之法人座談會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7754-2025-12-29-1759-5rax5d","company_id":"7754","company":"安基生技","market":"興櫃","industry":"生技醫療","date":"2025-12-29","time":"17:59:49","subject":"公告本公司董事會決議員工認股權憑證轉換普通股增資基準日","clause":"第9款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：安基生技（7754），2025-12-29 17:59，「公告本公司董事會決議員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7754-2025-12-29-1759-1md8tpl","company_id":"7754","company":"安基生技","market":"興櫃","industry":"生技醫療","date":"2025-12-29","time":"17:59:14","subject":"公告本公司董事會通過114年度員工認股權憑證發行及認股辦法","clause":"第9款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：安基生技（7754），2025-12-29 17:59，「公告本公司董事會通過114年度員工認股權憑證發行及認股辦法」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7754-2025-12-29-1758-1uhskx3","company_id":"7754","company":"安基生技","market":"興櫃","industry":"生技醫療","date":"2025-12-29","time":"17:58:49","subject":"公告本公司董事會決議辦理現金增資發行新股","clause":"第9款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：安基生技（7754），2025-12-29 17:58，「公告本公司董事會決議辦理現金增資發行新股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6676-2025-12-29-1758-5rax5d","company_id":"6676","company":"祥翊","market":"興櫃","industry":"生技醫療","date":"2025-12-29","time":"17:58:09","subject":"公告本公司董事會決議員工認股權憑證轉換普通股增資基準日","clause":"第9款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：祥翊（6676），2025-12-29 17:58，「公告本公司董事會決議員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-5312-2025-12-29-1750-1oykchj","company_id":"5312","company":"寶島科","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"17:50:34","subject":"公告本公司受邀參加國票證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-30","cite_as":"公開資訊觀測站重大訊息：寶島科（5312），2025-12-29 17:50，「公告本公司受邀參加國票證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8436-2025-12-29-1739-1bi2fou","company_id":"8436","company":"大江","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"17:39:30","subject":"本公司受邀參加台新證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-30","cite_as":"公開資訊觀測站重大訊息：大江（8436），2025-12-29 17:39，「本公司受邀參加台新證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1783-2025-12-29-1728-1bi2fou","company_id":"1783","company":"和康生","market":"上市","industry":"生技醫療","date":"2025-12-29","time":"17:28:10","subject":"本公司受邀參加台新證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-30","cite_as":"公開資訊觀測站重大訊息：和康生（1783），2025-12-29 17:28，「本公司受邀參加台新證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-29-1726-190mpt8","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-29","time":"17:26:22","subject":"更正實際定價日起二日內應申報相關資訊","clause":"第51款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-29 17:26，「更正實際定價日起二日內應申報相關資訊」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6586-2025-12-29-1608-19m50gr","company_id":"6586","company":"醣基","market":"興櫃","industry":"生技醫療","date":"2025-12-29","time":"16:08:09","subject":"公告本公司財務主管、會計主管暨代理發言人異動","clause":"第11款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：醣基（6586），2025-12-29 16:08，「公告本公司財務主管、會計主管暨代理發言人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4139-2025-12-29-1532-1wsvuta","company_id":"4139","company":"馬光-KY","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"15:32:14","subject":"公告本公司114年11月份自結合併財務報告之負債比率、流動比率及速動比率","clause":"第53款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：馬光-KY（4139），2025-12-29 15:32，「公告本公司114年11月份自結合併財務報告之負債比率、流動比率及速動比率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2025-12-29-1528-wjkoq4","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"15:28:35","subject":"公告本公司內部稽核主管異動案","clause":"第8款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2025-12-29 15:28，「公告本公司內部稽核主管異動案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6864-2025-12-29-1503-dqh4gv","company_id":"6864","company":"元樟生技","market":"興櫃","industry":"生技醫療","date":"2025-12-29","time":"15:03:07","subject":"公告本公司114年度現金增資收足股款暨增資基準日","clause":"第44款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：元樟生技（6864），2025-12-29 15:03，「公告本公司114年度現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2025-12-29-1108-1fqkmsr","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-12-29","time":"11:08:47","subject":"澄清媒體報導","clause":"第51款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-12-29 11:08，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6541-2025-12-29-0640-1i53vsi","company_id":"6541","company":"泰福-KY","market":"上市","industry":"生技醫療","date":"2025-12-29","time":"06:40:19","subject":"代重要子公司Tanvex BioPharma USA, Inc.公告向美國FDA提交生物相似藥TX05 (Herceptin Biosimilar)藥證申覆資料","clause":"第51款","fact_date":"2025-12-28","cite_as":"公開資訊觀測站重大訊息：泰福-KY（6541），2025-12-29 06:40，「代重要子公司Tanvex BioPharma USA, Inc.公告向美國FDA提交生物相似藥TX05 (Hercept」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2025-12-29-0626-c1z9ky","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2025-12-29","time":"06:26:13","subject":"生華科新藥CX-5461首次聯合AstraZeneca/第一三共開發之ADC藥物Trastuzumab Deruxtecan，用於HER2陽性實體腫瘤及乳癌之Phase1b臨床試驗，美國NCI已向FDA提出新增試驗申請。","clause":"第53款","fact_date":"2025-12-27","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2025-12-29 06:26，「生華科新藥CX-5461首次聯合AstraZeneca/第一三共開發之ADC藥物Trastuzumab Deruxtec」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}